still a good buy in?, page-3

Also noted that the guy who is managing the company George Tachas is the same guy who published the paper below as taken from the website..

The results from successful animal testing confirm its potential as a treatment for diseases associated with excessive growth hormone action published by Tachas et al, J Endocrinol, 2006 Apr; 189 (1): 147-54). These include acromegaly (abnormal growth of organs, face, hands and feet) and diabetic retinopathy a known major cause of blindness.

Must be the important drug to the company...